The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | Personalizing CLL treatment: MRD-guided therapy?
Alessandra Tedeschi, MD, PhD, of the Niguarda Cancer Center, Milan, Italy, gives us her insight into what the future may look like for personalized treatment in chronic lymphocytic leukemia (CLL). Dr Tedeschi discusses the potential use of measurable residual disease (MRD) measurement routinely to direct treatment cessation and decision-making. She also highlights the benefits that this may have for treatment cost and drug resistance. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
